Clinical Trials
120 trialsBrentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Tremelimumab
MedImmune LLC
LAG-MAPS
Intergroupe Francophone de Cancerologie Thoracique
MesoPDT
University Hospital, Lille
CheckMate 6DW
Bristol-Myers Squibb
CHIMERA
Istituto Oncologico Veneto IRCCS
......SMARTEST Trial......
University Health Network, Toronto
BIMES
Fundación GECP
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
IMPALA
University Hospital, Lille
NEMO
European Organisation for Research and Treatment of Cancer - EORTC
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
FAPI-PM
Aalborg University Hospital
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PENINSULA
Hyogo Medical University
NERO
University Hospital Southampton NHS Foundation Trust
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
PEMMELA
The Netherlands Cancer Institute
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Mateon Therapeutics
NIPU
Oslo University Hospital
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Sun Yat-sen University
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
PrE0505
PrECOG, LLC.
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
REFIT-MSS
Translational Research in Oncology
Diadem
Mario Negri Institute for Pharmacological Research
MiST
University of Leicester
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
European Organisation for Research and Treatment of Cancer - EORTC
Amatuximab
Morphotek
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Momotaro-Gene Inc.
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Alliance for Clinical Trials in Oncology